Edwards Lifesciences (NYSE: EW) Form 144 details 3,863-share planned sale

Rhea-AI Filing Summary

Edwards Lifesciences has a shareholder filing a Form 144 notice to sell up to 3,863 common shares through Charles Schwab on or about December 10, 2025, with an aggregate market value of $322,367. The shares to be sold were acquired on December 8, 2025 via a restricted stock lapse as equity compensation from Edwards Lifesciences Corporation.

During the prior three months, the same seller disposed of 21,487 Edwards Lifesciences shares on December 8, 2025 for gross proceeds of $1,831,006. Edwards Lifesciences had 580,300,000 shares outstanding, providing context for the relative size of these planned and recent sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	3863	322367.00	580300000	12/10/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/08/2025	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			3863	12/08/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bernard J Zovighian ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	12/08/2025	21487	1831006.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Edwards Lifesciences (EW) disclose?

The Form 144 discloses that a shareholder intends to sell up to 3,863 shares of Edwards Lifesciences common stock through Charles Schwab, with an aggregate market value of $322,367 and an approximate sale date of December 10, 2025.

How many Edwards Lifesciences (EW) shares did the insider recently sell?

In the past three months, the seller disposed of 21,487 Edwards Lifesciences shares on December 8, 2025, generating gross proceeds of $1,831,006.

How were the Edwards Lifesciences (EW) shares in the Form 144 acquired?

The 3,863 shares covered by the Form 144 were acquired on December 8, 2025 via a restricted stock lapse from Edwards Lifesciences Corporation as equity compensation.

What is the total number of Edwards Lifesciences (EW) shares outstanding?

The filing notes that Edwards Lifesciences had 580,300,000 shares of common stock outstanding, giving context to the size of the planned and recent share sales.

Which broker is handling the planned Edwards Lifesciences (EW) share sale?

The planned sale of 3,863 Edwards Lifesciences common shares is to be executed through Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake, TX 76262.

On which exchange are the Edwards Lifesciences (EW) shares listed in this Form 144?

The Form 144 indicates that the common shares referenced are listed on the NYSE.